Literature DB >> 23089459

Lower mortality from nasopharyngeal cancer in The Netherlands since 1970 with differential incidence trends in histopathology.

Melina Arnold1, Maarten A Wildeman, Otto Visser, Henrike E Karim-Kos, Jaap M Middeldorp, Renske Fles, I Bing Tan, Jan Willem Coebergh.   

Abstract

OBJECTIVE: Nasopharyngeal carcinoma (NPC) is rare in western countries albeit affected by common and unrelated phenomena: smoking less in men, more in women and immigration from China and North Africa. We studied trends in NPC incidence, tumour morphology, survival and mortality in order to assess progress against this cancer.
MATERIALS AND METHODS: A trend analysis was performed with nationwide incidence and survival data (from The Netherlands Cancer registry in 1989-2009), followed by analysis of mortality (data from Statistics Netherlands) covering the period 1970-2009, and calculating estimated percentages of change (EAPC) in both. According to the WHO classification we distinguished keratinizing SCC (WHO-I), differentiated (WHO-IIA) and undifferentiated (WHO-IIB) non-keratinizing carcinoma.
RESULTS: NPC incidence significantly decreased since 1989, especially in males (EAPC 1989-2009: -1.3; 95% CI: -2.5, -0.2) and in patients with keratinizing SCC (WHO-I) (EAPC: -3.6; 95% CI: -5.3, -1.8). By contrast, the incidence of differentiated non-keratinizing tumours (WHO-IIA) significantly increased in the same period (EAPC: 9.6; 95% CI: 5.6, 13.5). One- and three-year relative survival, as an indicator of disease-specific survival increased slightly from 79% to 81% and from 57% to 65% since 1989. NPC mortality significantly decreased since 1970 (EAPC: -1.2; 95% CI: -1.8, -0.5) and more pronounced since 1989 (EAPC: -3.0; 95% CI: -4.3, -1.6).
CONCLUSION: During the past two decades, the incidence of NPC in The Netherlands decreased mainly by less keratinizing, supposedly smoking-related NPC (WHO-I). However, the incidence of non-keratinizing NPC (WHO-IIA, B) increased, most likely due to EBV infection and thus related to higher immigration levels of people from high-incidence areas.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23089459     DOI: 10.1016/j.oraloncology.2012.09.016

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  12 in total

1.  Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group.

Authors:  Sharon D Stoker; Maarten A Wildeman; Zlata Novalic; Renske Fles; Vincent van der Noort; Remco de Bree; Weibel W Braunius; Guido B van den Broek; Bas Kreike; Kenneth W Kross; Hedy Juwana; Octavia Ramayanti; Sandra A W M Verkuijlen; Jan Paul de Boer; Astrid E Greijer; Jaap M Middeldorp; I Bing Tan
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-01       Impact factor: 2.503

2.  Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.

Authors:  Sharon D Stoker; Zlata Novalić; Maarten A Wildeman; Alwin D R Huitema; Sandra A W M Verkuijlen; Hedy Juwana; Astrid E Greijer; I Bing Tan; Jaap M Middeldorp; Jan Paul de Boer
Journal:  J Cancer Res Clin Oncol       Date:  2015-04-29       Impact factor: 4.553

3.  Nasopharyngeal carcinoma: 30-year experience of a single institution in a non-endemic area.

Authors:  J García-Lorenzo; N Farre; A Codina; O Gallego; M De Vega; X León
Journal:  Clin Transl Oncol       Date:  2017-01-24       Impact factor: 3.405

4.  Radiotherapy induces cell cycle arrest and cell apoptosis in nasopharyngeal carcinoma via the ATM and Smad pathways.

Authors:  Ming-Yi Li; Jin-Quan Liu; Dong-Ping Chen; Zhou-Yu Li; Bin Qi; Lu He; Yi Yu; Wen-Jin Yin; Meng-Yao Wang; Ling Lin
Journal:  Cancer Biol Ther       Date:  2017-09-02       Impact factor: 4.742

5.  Improved long-term results of intensity-modulated radiotherapy for a non-endemic European nasopharyngeal carcinoma cohort: single-center retrospective study.

Authors:  Eduardo Netto; Margarida Ferreira; Susana Esteves; Isabel Sargento; Teresa Alexandre; Rute Pocinho; Antonio Mota; Miguel Labareda; Miguel Rito; José Cabeçadas; Miguel Magalhães; Margarida Roldão
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-28

6.  Nasopharyngeal carcinoma incidence and mortality in China, 2013.

Authors:  Kuang-Rong Wei; Rong-Shou Zheng; Si-Wei Zhang; Zhi-Heng Liang; Zhu-Ming Li; Wan-Qing Chen
Journal:  Chin J Cancer       Date:  2017-11-09

7.  Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.

Authors:  Octavia Ramayanti; Sandra A W M Verkuijlen; Putri Novianti; Chantal Scheepbouwer; Branislav Misovic; Danijela Koppers-Lalic; Jan van Weering; Lisa Beckers; Marlinda Adham; Debora Martorelli; Jaap M Middeldorp; Dirk Michiel Pegtel
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

8.  The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up.

Authors:  San-Gang Wu; Chen-Lu Lian; Jun Wang; Wen-Wen Zhang; Jia-Yuan Sun; Qin Lin; Zhen-Yu He
Journal:  Ann Transl Med       Date:  2019-12

9.  Epstein-Barr virus nuclear antigen-1 is useful as therapeutic efficacy marker in serum but not in saliva of nasopharyngeal cancer patients who underwent radiotherapy.

Authors:  Yurnadi H Midoen; Dwi A Suryandari; Luluk Yunaini; Raden Susworo; Elza I Auerkari; Hans-Joachim Freisleben
Journal:  Ecancermedicalscience       Date:  2021-06-21

10.  Nasopharyngeal carcinoma incidence and mortality in China in 2009.

Authors:  Zhi-Jian Xu; Rong-Shou Zheng; Si-Wei Zhang; Xiao-Nong Zou; Wan-Qing Chen
Journal:  Chin J Cancer       Date:  2013-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.